Why the study?
Does galectin-9 administration alter myeloid suppressor cell phenotypes and expand regulatory T cells in a mouse model of CVB3-induced acute myocarditis?
Does galectin-9 administration alter myeloid suppressor cell phenotypes and expand regulatory T cells in a mouse model of CVB3-induced acute myocarditis?
Galectin-9 therapy may represent a useful approach to ameliorate CVB3-induced myocarditis by expanding regulatory T cells via myeloid suppressor cells.
Answers are grounded in this paper and cite their sources.
Galectin-9 may modulate immunity in murine myocarditis; hypothesis-generating and leaves open human translation.
The objective of the study was to explore the effects of galectin-9 on myeloid suppressor cells in Coxsackievirus B3 (CVB3)-induced myocarditis and the possible mechanisms involved. For this purpose, BALB/c male mice were infected with CVB3 on day 0 and then received intraperitoneal (IP) administration of recombinant galectin-9 or phosphate-buffered saline (PBS) daily from day 3 to day 7. The phenotypes and functions of myeloid suppressor cells were evaluated. The role and mechanism of myeloid suppressor cells and subsets in CVB3-induced myocarditis in vitro were explored. We found that galectin-9 remarkably increased the frequencies of CD11b+Gr-1+ cells in the cardiac tissue and spleen with myocarditis. Ly-6G+ cells were decreased and Ly-6C+ cells were increased in galectin-9-treated mice. In addition, CD11b+Gr-1+ cells were highly effective in suppressing CD4+ T cells. Moreover, our data demonstrate that CD11b+Gr-1+ cells are capable of expanding regulatory T cells (Tregs) from a preexisting population of natural Tregs, which depends on IL-10 but not TGF-β. Our results indicate that galectin-9 therapy may represent a useful approach to ameliorate CVB3-induced myocarditis.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: